(8 intermediate revisions by the same user not shown) | |||
Line 162: | Line 162: | ||
#title #header1{ | #title #header1{ | ||
display:inline-block; | display:inline-block; | ||
− | margin-left: | + | margin-left:8%; |
− | margin-right: | + | margin-right:8%; |
margin-bottom:100px; | margin-bottom:100px; | ||
− | width: | + | width:280px; |
} | } | ||
#title #header2{ | #title #header2{ | ||
display:inline-block; | display:inline-block; | ||
− | margin-left: | + | margin-left:8%; |
− | margin-right: | + | margin-right:8%; |
margin-bottom:100px; | margin-bottom:100px; | ||
− | width: | + | width:250px; |
} | } | ||
#title span{ | #title span{ | ||
Line 224: | Line 224: | ||
margin: 0; | margin: 0; | ||
font-weight: normal; | font-weight: normal; | ||
− | font-size: | + | font-size: 10pt; |
color: #70C05B; | color: #70C05B; | ||
cursor: initial; | cursor: initial; | ||
Line 388: | Line 388: | ||
<ul class="drop-menu menu-1"> | <ul class="drop-menu menu-1"> | ||
<a href="https://2017.igem.org/Team:Kent/Description"><li>Description</li></a> | <a href="https://2017.igem.org/Team:Kent/Description"><li>Description</li></a> | ||
− | <a href="https://2017.igem.org/Team:Kent/ | + | <a href="https://2017.igem.org/Team:Kent/Model"><li>Modelling</li></a> |
<a href="https://2017.igem.org/Team:Kent/Results"><li>Results</li></a> | <a href="https://2017.igem.org/Team:Kent/Results"><li>Results</li></a> | ||
− | + | ||
− | + | ||
</ul> | </ul> | ||
<li> | <li> | ||
<a href="#">Parts</a> | <a href="#">Parts</a> | ||
<ul class="drop-menu menu-2"> | <ul class="drop-menu menu-2"> | ||
− | + | ||
<a href="https://2017.igem.org/Team:Kent/Basic_Part"><li>Basic Parts</li></a> | <a href="https://2017.igem.org/Team:Kent/Basic_Part"><li>Basic Parts</li></a> | ||
− | + | ||
− | + | ||
</ul> | </ul> | ||
Line 421: | Line 419: | ||
<ul class="drop-menu menu-2"> | <ul class="drop-menu menu-2"> | ||
<a href="https://2017.igem.org/Team:Kent/Safety"><li>Project Safety</li></a> | <a href="https://2017.igem.org/Team:Kent/Safety"><li>Project Safety</li></a> | ||
− | + | ||
</ul> | </ul> | ||
</li> | </li> | ||
Line 445: | Line 443: | ||
</nav> | </nav> | ||
<div id ="title"> | <div id ="title"> | ||
− | <img src = "https://static.igem.org/mediawiki/2017/thumb/ | + | <img src = "https://static.igem.org/mediawiki/2017/thumb/1/12/T--Kent--FutureHeader.png/800px-T--Kent--FutureHeader.png" id="header1"> |
− | <span> | + | <span>Future Ideas</span> |
− | <img src = "https://static.igem.org/mediawiki/2017/thumb/ | + | <img src = "https://static.igem.org/mediawiki/2017/thumb/7/7e/T--Kent--FutureHeader2v2.png/603px-T--Kent--FutureHeader2v2.png" id="header2"> |
</div> | </div> | ||
<nav class="droptext arrows"> | <nav class="droptext arrows"> | ||
<header class="hull"> | <header class="hull"> | ||
− | <label for="acc-close" class="hull-title"> | + | <label for="acc-close" class="hull-title">Due to the simple nature of our dCas13a protein construct, it can be utilized and ‘personalized’ for a |
+ | variety of purposes. Our main objectives range from ‘near’ future, to ‘future’.</label> | ||
</header> | </header> | ||
<input type="radio" name="droptext" id="cb1" /> | <input type="radio" name="droptext" id="cb1" /> | ||
<section class="hull"> | <section class="hull"> | ||
− | <label class="hull-title" for="cb1"> | + | <label class="hull-title" for="cb1">Near Future</label> |
<label class="hull-close" for="acc-close"></label> | <label class="hull-close" for="acc-close"></label> | ||
− | <div class="hull-content"> | + | <div class="hull-content">Although the processes within the central dogma have been studied and thoroughly characterized, |
− | + | recent studies suggest mRNA localization is a way of controlling and regulating protein production. ¹ This | |
− | + | mechanism appears to be similar to an induced suppressor that binds to DNA, thereby preventing its | |
− | + | transcription, except there are significantly more (regulating) factors involved. Unfortunately, our | |
+ | knowledge is very limited as mRNA’s dynamic nature makes it significantly more difficult to study. | ||
+ | As our protein, LuCAS, has the ability to attach to, and track any RNA, given it has its complementary | ||
+ | crRNA sequence, the main objective is to track and investigate mRNA localization. LuCAS is sensitive and | ||
+ | selective to singular basepairs, making it a reliable tracking tool without altering the cell and its | ||
+ | intracellular function itself. | ||
<br> | <br> | ||
When making the LB we also made another litre batch and added 15g of agar extract to be able to | When making the LB we also made another litre batch and added 15g of agar extract to be able to | ||
Line 467: | Line 471: | ||
<input type="radio" name="droptext" id="cb2" /> | <input type="radio" name="droptext" id="cb2" /> | ||
<section class="hull"> | <section class="hull"> | ||
− | <label class="hull-title" for="cb2"> | + | <label class="hull-title" for="cb2">Future</label> |
<label class="hull-close" for="acc-close"></label> | <label class="hull-close" for="acc-close"></label> | ||
− | <div class="hull-content"> | + | <div class="hull-content">In a variety of disease states, mRNA could be used as a ‘biomarker’ and therapeutic target. Oncogenes |
− | + | for example, such as Epidermal growth factor receptor (EGFR), are often overexpressed early in cancers | |
− | to | + | and treatment courses based on the type of mutations causing the cancer have been shown to be |
− | + | crucial to treatment success; in this case for example, tyrosine kinase inhibitors or monoclonal | |
− | + | antibodies. Tools like LuCAS could potentially quantify and elucidate hyperproliferation and even qualify | |
− | + | mRNA as therapeutic target to halt hyper proliferation of key ‘driver’ genes by targeting their mRNA. | |
− | + | Furthermore, monitoring mRNA expression in patients suffering chronic viral infections, such as HIV or | |
− | + | hepatitis B, can help pinpoint disease progression and aid in treatment path selection, as disease | |
− | + | progression varies individually. HIV genes can be classified in early and late expression, with their | |
− | + | detection of corresponding mRNA, via LuCAS, helping to narrow down the stage of disease. | |
− | + | The possible applications of LuCAS are many, as we simply propose a reliable and selective way to target | |
− | + | mRNA in vivo without altering cellular functions; be it for research, diagnostics or therapeutics. | |
− | + | ~ LuCas is still a toddler and these are his first baby steps, we can’t wait to see him prosper and grow | |
− | + | into a young man that will change the world for the better</div> | |
− | + | ||
− | + | ||
− | and | + | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</section> | </section> | ||
+ | |||
<input type="radio" name="droptext" id="acc-close" /> | <input type="radio" name="droptext" id="acc-close" /> | ||
− | <input type="radio" name="droptext" id=" | + | <input type="radio" name="droptext" id="cb3" /> |
<section class="hull"> | <section class="hull"> | ||
− | <label class="hull-title" for=" | + | <label class="hull-title" for="cb3">References</label> |
<label class="hull-close" for="acc-close"></label> | <label class="hull-close" for="acc-close"></label> | ||
− | <div class="hull-content"> | + | <div class="hull-content">Kejiou, N. S. and Palazzo, A. F. (2017), mRNA localization as a rheostat to regulate subcellular gene |
− | + | expression. WIREs RNA, 8: n/a, e1416. doi:10.1002/wrna.1416</div> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | a | + | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</section> | </section> | ||
+ | |||
<input type="radio" name="droptext" id="acc-close" /> | <input type="radio" name="droptext" id="acc-close" /> | ||
</nav> | </nav> |
Latest revision as of 03:21, 16 December 2017
Future Ideas